One of the most fatal and chronic disorder now a day is Cancer. It is
a highly hazardous disease with an extremely high mortality rate due
to its highly invasive nature and prolonged duration of disease. Bone
cancer is one the types of cancer in which the tissues of bone start
growing in uncontrollable manner. This growth can be benign or
malignant. In most of the cases, the bone cancer is a result from
other cancers.
Report Overview @
https://www.transparencymarketresearch.com/bone-cancer-market.html
The major and primary symptom of the bone cancer is severe and
intolerable bone pain. This pain increases over the period of time.
In addition to pain, symptoms like weight loss, fatigue, bone crack,
fever, muscle pain, osteoporosis, and osteopenia are also identified.
The diagnostic tests may preliminary include deep study of patient’s
history and reasons of pain. Afterwards, the diagnosis of the bone
cancer is carried out by using some imaging studies, such as, CT
scan, MRI, bone scanning, and PET scanning. Biopsy test is also used
for the diagnosis and confirmation of the disease.
The market of bone cancer is segmented on the basis of types of bone
cancer, such as, primary bone cancer and secondary bone cancer.
Primary bone cancer is the type of cancer that originates from rapid
and uncontrollable growth of the bone and related tissues. Whereas,
secondary cancer is a type of bone cancer, in which, the cancer is
originated to some other site of the body and metastasize to the bone
structure. The bone cancer is also classified as, osteosarcoma,
Ewing’s sarcoma, chondrosarcoma, chordomas, fibrosarcoma, and
admantinomas.
Request a Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14948
The market is also segmented on the basis of therapies and treatments
available, such as radiation therapy, chemotherapy, cryosurgery and
surgical treatments. Limb amputation surgery, limb salvage surgery or
limb sparing surgery are the major surgical practices used to treat
bone cancer. Whereas, in radiation therapy, high energy X-rays or
gamma-rays are used to destroy the tumors. Chemotherapy is a
pharmacological treatment by using anti-cancer drugs either orally or
parenterally. Major drugs include strontium-89 chloride,
bisphosphonates, methotrexate, denosumab, doxorubicin and many
others. Cryosurgery is also sometimes used to treat the bone cancer.
In addition, the market is segmented on the basis of geography, such
as North America, Europe, Asia-Pacific and Rest of the World (RoW).
The North American region is the most dominating market in the world,
owing to rapidly growing incidences of bone cancers and rising focus
towards R&D for bone tumor treatments. On the other hand,
Asia-Pacific and RoW regions are the most promising markets in the
upcoming period, owing to rise in awareness of bone cancer, its
chronic impacts and its treatments.
Although it accounts for much less than one percent of all cancers,
the market of bone cancer is expected to grow at a steady rate during
the forecast period from 2016 – 2024. This growth is anticipated to
be driven by various factors, such as, R&D practices running
across the globe, rising awareness amongst the population for bone
cancer and other bone diseases, increasing medical infrastructure and
technological advancements. Owing to R&D practices, a number of
drugs and formulations are under pipeline studies and are expected to
enter in the market during forecast period. However, low prevalence
of the disease is the major hurdle in the market growth, followed by
high cost of R&D, diagnosis and treatment.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=14948
According to American Cancer Society estimates, approximately 3,300
new cases of bone cancer are expected to diagnose in 2016, out of
which, around 1490 deaths are expected due to bone cancer. Hence,
this very low prevalence is the major hurdle in the market growth.
The major players operating in this market include Amgen, Inc.,
Actavis plc, Novartis International AG, Debiopharm Group, Pfizer,
Inc., and Eli Lilly and Company amongst others.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment